Amyotrophic Lateral Sclerosis Type 24 (ALS24 / NEK1-Associated): A Patient Guide

Amyotrophic Lateral Sclerosis Type 24 (ALS24) is a term used when ALS is associated with a specific disease-associated variant in the NEK1 gene. While receiving a genetic label can feel like a daunting addition to an already difficult diagnosis, understanding the nature of NEK1 helps clarify your personal health picture. This gene provides the instructions for a protein that acts as a cellular guardian. Laboratory research suggests it helps motor neurons repair their DNA and maintain the internal “highways”—known as microtubules—that transport essential nutrients throughout the cell ^[1][2]. When this protein does not function optimally, laboratory models indicate the motor neurons can become more vulnerable to stress and degeneration ^[3].

It is vital to understand that a genetic finding alone does not diagnose ALS; ALS remains a clinical diagnosis made by a neurologist. Furthermore, NEK1 is generally classified as a susceptibility gene. Unlike some other genetic variants that carry a very high risk of disease, having a NEK1 variant increases your risk but does not guarantee the disease will develop—a concept known as incomplete penetrance ^[4]. Scientists hypothesize that for someone with this variant to develop ALS, other genetic, environmental, or age-related factors may contribute, though these mechanisms remain under study and are not yet fully understood ^[5]. For many people, the discovery of a NEK1 variant is just one piece of a complex puzzle, which explains why some family members may carry the same gene variant for a lifetime without ever showing symptoms ^[6][7].

In your day-to-day life and medical care, NEK1-associated ALS behaves very much like other forms of ALS. The symptoms, the rate of progression, and the way the disease affects the body generally mirror what is seen in people without a known genetic cause ^[8]. Because of this, the roadmap for your care remains the recommended standard used for all ALS patients: a robust, multidisciplinary approach. This means working with a team of experts—including neurologists, respiratory therapists, speech-language pathologists, and nutritionists—who focus on protecting your breathing, maintaining your nutrition, and managing symptoms to ensure the highest possible quality of life ^[9][10].

The treatment strategy centers on proactive support and the use of evidence-based medications to manage symptoms and potentially slow the progression of the disease. While gene-targeted therapies for NEK1 are still in the preclinical and research phases, the global scientific community is focused on the very pathways this gene affects, such as DNA repair and cellular stability ^[2]. By engaging with a specialized clinic and staying informed about these developments, you are ensuring that your care is grounded in the best available science. You are not defined by a gene variant; you are a person at the center of a dedicated care team working to help you navigate this journey with dignity and support ^[11].